Pharmaceutical Granulation Equipment: Market Size & Forecast 2026

Pharmaceutical granulation equipment encompasses wet granulators, dry granulators, and fluid-bed dryers used to convert fine powders into free-flowing granules suitable for compression into tablets or filling into capsules. The market was valued at approximately $5.86 billion in 2025 and is expected to grow to over $8 billion by 2035, reflecting long-term structural demand from the broader pharmaceutical manufacturing sector. Growth is underpinned by the expanding global volume of drug production, stricter regulatory requirements for content uniformity, and the shift toward continuous processing lines.

• •Market valued at roughly $5.86 billion in 2025, on a trajectory toward approximately $8.19 billion by 2035
• •Technology categories include wet granulation, dry granulation (slugging/roller compaction), and continuous granulation systems
• •Regulatory mandates for consistent content uniformity and particle size distribution drive equipment upgrades across manufacturing facilities

The expanding global pharmaceutical market, projected to exceed $3.2 trillion, directly fuels demand for upstream processing equipment including granulators. The rapid growth of generic drugs and biosimilars production requires high-throughput, reliable granulation lines to meet volume targets while satisfying pharmacopeial standards. Continuous manufacturing adoption is accelerating as regulators encourage process intensification, and contract development and manufacturing organizations are investing in modular, scalable granulation platforms.

• •Generic and biosimilar drug proliferation increases demand for cost-effective, high-volume granulation capacity
• •Regulatory acceptance of continuous manufacturing (e.g., FDA Quality by Design initiatives) encourages capital investment in continuous granulation equipment
• •Geographic expansion of pharmaceutical manufacturing in Asia-Pacific and emerging markets supports long-term demand

The market is segmented by granulation method, product type (tablets versus capsules), and end-user type (in-house manufacturing versus contract manufacturers). Geographically, established markets in North America and Europe lead in equipment sophistication and regulatory-driven upgrades, while Asia-Pacific represents the fastest-growing regional market driven by large-scale generics production and infrastructure investment. Emerging economies in Latin America and the Middle East contribute steadily as local pharmaceutical capacity expands.

• •Wet granulation holds the largest share, while continuous granulation is the fastest-growing sub-segment
• •North America and Europe lead in advanced equipment deployment, with strong replacement and upgrade demand
• •Asia-Pacific is the fastest-growing region, supported by generics manufacturing expansion in key production hubs

Who are the notable companies in the industry?

The market exhibits a moderately fragmented competitive structure with a mix of large diversified industrial equipment suppliers and specialized pharmaceutical process equipment manufacturers. Integrated producers offering broad portfolios across mixing, granulation, drying, and coating dominate in established markets, while narrower specialists compete on granulation-specific innovation and process customization. Regional capacity is concentrated in North America and Western Europe for high-end continuous and specialized systems, with significant mid-tier manufacturing presence across Germany, Italy, India, and China.

• •Competitive structure ranges from large diversified industrial equipment conglomerates to mid-tier and niche specialists focused on pharmaceutical processing
• •Main technology routes include high-shear wet granulation, fluid-bed granulation/drying, roller compaction (dry granulation), and twin-screw continuous granulation
• •Regional manufacturing and R&D capacity is heaviest in North America and Western Europe, with growing production bases in India and China serving cost-sensitive and regional markets

What are the recent trends and outlook?

The industry is moving decisively toward continuous manufacturing architectures, with twin-screw granulation and real-time process analytical technology (PAT) becoming standard in new plant design. Digitalization, including inline monitoring and AI-assisted process control, is reshaping equipment specifications and aftermarket service offerings. Over the forecast horizon, consolidation among mid-tier manufacturers, rising retrofit demand from older batch facilities converting to continuous lines, and growing biopharmaceutical solid-dosage production collectively support a positive long-term outlook.

• •Continuous granulation technologies, particularly twin-screw systems, are displacing traditional batch equipment in new facility buildouts
• •Real-time monitoring and PAT integration are becoming baseline expectations for regulatory-compliant equipment purchases
• •Biopharmaceutical solid-dosage and fixed-dose combination products are creating demand for more flexible and precision-engineered granulation platforms